A protein-ligand interaction database for drug discovery
Harnessing data from the growing number of protein-ligand complexes in the Protein Data Bank (PDB) is an important task in drug discovery. In order to benefit from the abundance of three-dimensional structures, structural data must be integrated with sequence as well as chemical data and the protein-small molecule interactions characterised structurally at the inter-atomic level. Here, we present CREDO, a new publicly available database of protein-ligand interactions, which represents contacts as structural interaction fingerprints, implements novel features and is completely scriptable through its application programming interface (API). Features of CREDO include implementation of molecular shape descriptors with Ultrafast Shape Recognition (USR), fragmentation of ligands in the PDB, sequence-to-structure mapping and the identification of approved drugs. Selected analyses of these key features are presented to highlight a range of potential applications of CREDO. We believe that the free availability and numerous features of CREDO database will be useful not only for commercial but also for academia-driven drug discovery programmes.
TIMBAL holds small molecules disrupting protein-protein interactions
To date, drug discovery has focused in the main part on a handful of targets that meet the "classical" druggable criteria: being linked to disease and having a beautiful pocket able to bind a small drug-like molecule (Hopkins and Groom, 2002). However the successes of monoclonal antibodies as therapeutic agents are changing the perspective of what makes a drug target. These biologicals disrupt multi-protein complexes, which are the key points of almost all processes in living organisms. Still, antibodies being expensive and difficult to administer are not the ideal drugs, and they target only extra cellular molecules. In recent years, growing evidence of the possibility of modulation of protein-protein interactions by small molecules is opening the door for new approaches and concepts in drug discovery (Whitty and Kumaravel, 2006). TIMBAL aims to be a resource which will give insights in the type of molecules favoured by protein interfaces and in the type of interactions these systems present. TIMBAL is a hand-curated relational database in MyQSL, containing small molecules inhibiting protein-protein interactions from the literature. It is also compatible with other structural databases within the Department: PICCOLO (protein-protein interactions from the PDB, Bickerton and Blundell), CREDO (ligand-protein interactions from the PDB, Schreyer and Blundell), BIPA (protein-DNA interactions from the PDB, Lee and Blundell). Chem Biol Drug Des. 2009. 74(5):457-67
Biological database for Interation between Protein and nucleic Acid
Structurally-characterized protein-protein interactions described at atomic level
The sequencing of the human genome provides the parts list for understanding cellular processes. However, as 70% of eukaryotic genes workthrough multi-protein systems, it is only through detailed study of the interactions of these components, that a more complete, systems-level understanding can be gained. PICCOLO is a comprehensive database of structurally characterized protein interactions that enables a variety of analyses to be performed concerning interface properties including residue propensity, hydropathy, polarity, interface size, sequence entropy and residue contact preference.
Homologous Structure Alignment Database
The database provides annotated structural alignments in various formats, superimposed structures, homologous SWISS-PROT/TrEMBL sequences, PROSITE annotation, links to other databases (Pfam, SMART) and the alignment and search interface to the program FUGUE.
Environment Specific Substitution Table